Lisata Therapeutics, Inc.

NasdaqCM:LSTA Stock Report

Market Cap: US$24.2m

Lisata Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Lisata Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

0.4%

Buyback Yield

Total Shareholder Yield0.4%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Jul 15
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Mar 22
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Sep 14

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Aug 04

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

May 02
We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Jan 05
We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

May 09
Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

Caladrius suspends CLBS119 COVID-19 study

Dec 14

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LSTA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LSTA's dividend payments have been increasing.


Dividend Yield vs Market

Lisata Therapeutics Dividend Yield vs Market
How does LSTA dividend yield compare to the market?
SegmentDividend Yield
Company (LSTA)n/a
Market Bottom 25% (US)1.3%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (LSTA) (up to 3 years)n/a

Notable Dividend: Unable to evaluate LSTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LSTA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LSTA's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LSTA has not reported any payouts.


Discover strong dividend paying companies